Business Context and Reporting Period
This Form 8-K was filed by Ocuphire Pharma, Inc. (trading symbol: OCUP) on December 6, 2022. The report discloses a material event under Item 8.01 Other Events, specifically the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the company's product candidate, Nyxol.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory milestone and does not contain financial statements or performance data.
Material Changes and Events
- NDA Submission: On December 6, 2022, Ocuphire Pharma submitted an NDA for Nyxol.
- Indication: The application seeks approval for Nyxol to reverse pharmacologically-induced mydriasis (pupil dilation) caused by adrenergic agonists (e.g., phenylephrine), parasympatholytic agents (e.g., tropicamide), or a combination thereof.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future performance, or a detailed risk factor analysis beyond the standard regulatory context of an NDA submission. The document notes that information on external websites referenced in the associated press release is not incorporated by reference.
Investor Verification Checklist
- Verify the status of the FDA review for the Nyxol NDA submitted on December 6, 2022.
- Review the full text of the press release (Exhibit 99.1) for details on the clinical data supporting the submission.
- Confirm the company's current cash runway and capital requirements, as this filing does not disclose liquidity metrics.
- Monitor for potential FDA responses, such as a Complete Response Letter or approval, which will impact the company's valuation.